See the DrugPatentWatch profile for tigecycline

Tigecycline: A Broad-Spectrum Antibiotic with Increased Liver Risk for Certain Groups

Tigecycline, a broad-spectrum antibiotic, has revolutionized the treatment of severe infections. However, its use is not without risks, particularly for certain groups of individuals. In this article, we will explore the groups with increased liver risk from tigecycline and discuss the implications for healthcare providers and patients.

What is Tigecycline?

Tigecycline is a glycylcycline antibiotic that works by inhibiting protein synthesis in bacteria. It is commonly used to treat severe infections, such as hospital-acquired pneumonia, ventilator-associated pneumonia, and skin and soft tissue infections.

Groups with Increased Liver Risk from Tigecycline

Several groups of individuals have been identified as being at increased risk of liver damage from tigecycline. These include:

1. Elderly Patients

Elderly patients are more susceptible to liver damage due to decreased liver function and increased sensitivity to medications. A study published in the Journal of Clinical Pharmacology found that elderly patients were more likely to experience liver enzyme elevations when taking tigecycline compared to younger patients (1).

2. Patients with Pre-Existing Liver Disease

Patients with pre-existing liver disease, such as cirrhosis or hepatitis, are at increased risk of liver damage from tigecycline. A study published in the Journal of Antimicrobial Chemotherapy found that patients with liver disease were more likely to experience liver enzyme elevations and liver failure when taking tigecycline (2).

3. Patients with Renal Impairment

Patients with renal impairment are at increased risk of liver damage from tigecycline due to the antibiotic's ability to accumulate in the body. A study published in the Journal of Clinical Pharmacology found that patients with renal impairment were more likely to experience liver enzyme elevations when taking tigecycline compared to patients with normal renal function (3).

4. Patients Taking Concomitant Medications

Patients taking concomitant medications, such as warfarin or statins, are at increased risk of liver damage from tigecycline. A study published in the Journal of Clinical Pharmacology found that patients taking concomitant medications were more likely to experience liver enzyme elevations when taking tigecycline compared to patients not taking concomitant medications (4).

5. Patients with Malnutrition

Patients with malnutrition are at increased risk of liver damage from tigecycline due to decreased liver function and increased sensitivity to medications. A study published in the Journal of Parenteral and Enteral Nutrition found that patients with malnutrition were more likely to experience liver enzyme elevations when taking tigecycline compared to patients with normal nutrition (5).

Conclusion

Tigecycline is a broad-spectrum antibiotic that has revolutionized the treatment of severe infections. However, its use is not without risks, particularly for certain groups of individuals. Healthcare providers should be aware of the increased liver risk associated with tigecycline in elderly patients, patients with pre-existing liver disease, patients with renal impairment, patients taking concomitant medications, and patients with malnutrition. By taking these risks into consideration, healthcare providers can better manage the use of tigecycline and minimize the risk of liver damage.

Key Takeaways

* Elderly patients are more susceptible to liver damage from tigecycline
* Patients with pre-existing liver disease are at increased risk of liver damage from tigecycline
* Patients with renal impairment are at increased risk of liver damage from tigecycline
* Patients taking concomitant medications are at increased risk of liver damage from tigecycline
* Patients with malnutrition are at increased risk of liver damage from tigecycline

FAQs

1. What is tigecycline used to treat?

Tigecycline is used to treat severe infections, such as hospital-acquired pneumonia, ventilator-associated pneumonia, and skin and soft tissue infections.

2. Who is at increased risk of liver damage from tigecycline?

Elderly patients, patients with pre-existing liver disease, patients with renal impairment, patients taking concomitant medications, and patients with malnutrition are at increased risk of liver damage from tigecycline.

3. What are the symptoms of liver damage from tigecycline?

Symptoms of liver damage from tigecycline may include jaundice, fatigue, nausea, and abdominal pain.

4. How can healthcare providers minimize the risk of liver damage from tigecycline?

Healthcare providers can minimize the risk of liver damage from tigecycline by monitoring patients for liver enzyme elevations and adjusting dosing as necessary.

5. Is tigecycline safe for use in patients with liver disease?

Tigecycline may not be safe for use in patients with liver disease, as it can accumulate in the body and cause liver damage. Healthcare providers should carefully consider the risks and benefits of using tigecycline in patients with liver disease.

References

1. "Pharmacokinetics and pharmacodynamics of tigecycline in elderly patients" (Journal of Clinical Pharmacology, 2015)
2. "Tigecycline-induced liver injury in patients with liver disease" (Journal of Antimicrobial Chemotherapy, 2013)
3. "Pharmacokinetics of tigecycline in patients with renal impairment" (Journal of Clinical Pharmacology, 2012)
4. "Concomitant use of tigecycline and warfarin: a retrospective analysis" (Journal of Clinical Pharmacology, 2014)
5. "Tigecycline-induced liver injury in patients with malnutrition" (Journal of Parenteral and Enteral Nutrition, 2016)

Cited Sources

1. DrugPatentWatch.com. (2022). Tigecycline Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent-expiration/tigecycline>
2. Centers for Disease Control and Prevention. (2022). Tigecycline. Retrieved from <https://www.cdc.gov/drugresistance/tigecycline.html>
3. World Health Organization. (2022). Tigecycline. Retrieved from <https://www.who.int/medicines/areas/trade_law/tigecycline/en/>